Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88615 | 1.00 | EGFR (0.41) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| Hydrochloric Acid SCHEMBL29733094 | 0.97 | EGFR (0.39) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| Hydrochloric Acid SCHEMBL29733087 | 0.97 | EGFR (0.39) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1285336 | 0.70 | ALDH1A1 (0.39) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3831708 | 0.70 | — | — | |
| SCHEMBL4937147 | 0.70 | ALDH1A1 (0.39) | MAPTALDH1A1ACHETSHRMAPK14 | |
| Strinoline SCHEMBL11278670 | 0.69 | GPR3 (0.44) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3819567 | 0.69 | — | — | |
| SCHEMBL8401811 | 0.69 | PIK3CG (0.47) | EGFRMAPTALDH1A1MAP4K4DYRK1A | |
| SCHEMBL6028972 | 0.69 | NQO2 (0.43) | MAPTALDH1A1MAP4K4PIM1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853730-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | claimed |
| EP-3634953-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-01-03 | — | — | EP | claimed |
| CN-116905240-A | Automobile skylight composite fabric and preparation method thereof | 金华市华尔汽车饰件有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115772156-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2023-03-10 | — | — | CN | claimed |
| CN-114853730-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | claimed |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| CN-116969901-B | Preparation method of 1,2, 4-benzotriazine derivative | 浙江师范大学 | 2025-09-16 | — | — | CN | disclosed |
| CN-116969901-B | Preparation method of 1,2, 4-benzotriazine derivative | 浙江师范大学 | 2025-09-16 | — | — | CN | disclosed |
| CN-116905240-B | Automobile skylight composite fabric and preparation method thereof | 金华市华尔汽车饰件有限公司 | 2025-08-26 | — | — | CN | disclosed |
| CN-119817591-A | Application of benzo-1, 2, 4-triazineoxazepine compound | 河北农业大学 | 2025-04-15 | — | — | CN | disclosed |
| EP-4508052-A1 | NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2025-02-19 | — | — | EP | disclosed |
| CN-109643758-B | Crosslinked p-type dopants for p-type doping of organic hole conductors | 默克专利股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115772156-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2023-03-10 | — | — | CN | disclosed |
| US-20230064948-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| CN-115611824-A | Nano-particles based on benzotriazine free radical compounds, preparation method and application of nano-particles in scavenging active oxygen of cells | 郑州大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-115611824-A | Nano-particles based on benzotriazine free radical compounds, preparation method and application of nano-particles in scavenging active oxygen of cells | 郑州大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-114853730-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022158610-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022075486-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, XDH, SLC10A1 | EGFR 360/4885PI4KA 3829/4885PI4K2B 3624/4885 |
| US-20230064948-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1131/4885PI4KA 4124/4885PI4K2B 4497/4885 |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1131/4885PI4KA 4124/4885PI4K2B 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.